The Immunosuppression Balancing Act: Preserving Long-Term Allograft Function for Optimal Patient Outcomes
Premiere Date: Friday, June 2, 2017This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Saturday, June 2, 2018
Note: Credit Is No Longer Available
 | Flavio Vincenti, MD (Moderator) Professor of Clinical Medicine and Surgery Medical Director, Kidney-Pancreas Program University of California San Francisco San Francisco, CA |
 | John R. Lake, MD Professor of Medicine and Surgery University of Minnesota Medical School Executive Medical Director, Solid Organ Transplantation Program University of Minnesota Medical Center Minneapolis, MN |
The current goal of transplant medicine and immunology is to develop strategies to extend the life and functionality of every allograft. Outcomes of renal and liver transplantation have improved; yet, allograft loss remains a substantial problem associated with increased morbidity, mortality, and costs.1
Education to transplant clinicians about evaluating all aspects of post-transplant care, including regular monitoring, can lead to a reduction in allograft dysfunction or loss. In addition, improving the patient-provider dialogue can foster adherence to treatment and careful monitoring of medication levels to maintain quality of life. Patient perspectives, integrated in the symposium design, highlight the challenges and opportunities to coordinating care with patients in alignment with the priorities of the National Quality Strategy.
This CME Outfitters 75-minute symposium features expert faculty presenting the latest evidence on antibody-mediated complications, regular monitoring strategies to optimize immunosuppression, and ways to engage patients to promote adherence and improve outcomes.
Reference:
Sharma S, Oliver K, Mudge DW. Advances in antibody mediated rejection. Chapter 20. In: Current Issues and Future Direction in Kidney Transplantation. InTech Open Website. http://cdn.intechopen.com/pdfs-wm/42886.pdf. Published 2013.
At the end of this CE activity, participants should be able to:
- Monitor levels of immunosuppression in transplant recipients at least every three months to document success and long-term survival.
- Assess for DSA HLA antibodies to prevent AMR in kidney and liver transplants.
- Develop a long-term strategy to promote medication adherence through patient engagement and education.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Explain how monitoring levels of immunosuppression can lead to success and long-term survival of transplant recipients.
- Describe how to assess for DSA HLA antibodies to prevent AMR in kidney and liver transplants.
- Identify a long-term strategy to promote medication adherence through patient engagement and education.
Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Transplant medicine and immunology specialists, physician assistants, nurse practitioners, nurses, and pharmacists who manage transplant patients.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC,designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.25 contact hours
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.25 contact hours of pharmacotherapeutic contact hour.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 CreditTM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.1.25 contact hours (0.10CEUs) Universal Activity Number:
0376-0000-17-018-H01-P
Type: knowledge-based
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/22267 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Vincenti reports that he receives research support from Alexion; Astellas Pharma US, Inc.; Bristol-Myers Squibb Company; Genentech, Inc; Immucor; and Novartis Pharmaceuticals Corporation.
Dr. Lake reports that he receives grants from Eisai Inc.; Mallinckrodt Pharmaceuticals; and Ocera Therapeutics, Inc. He receives speaker's fees from Novartis Pharmaceuticals Corporation and serves as a consultant for Novartis Pharmaceuticals Corporation; and Vital Therapies, Inc.
Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.
Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV-074-060217-45
